2023
Delirium among people aging with and without HIV: Role of alcohol and Neurocognitively active medications
Akgün K, Krishnan S, Tate J, Bryant K, Pisani M, Re V, Rentsch C, Crothers K, Gordon K, Justice A, team F. Delirium among people aging with and without HIV: Role of alcohol and Neurocognitively active medications. Journal Of The American Geriatrics Society 2023, 71: 1861-1872. PMID: 36786300, PMCID: PMC10258127, DOI: 10.1111/jgs.18265.Peer-Reviewed Original ResearchConceptsAlcohol Use Disorders Identification Test-ConsumptionActive medicationAlcohol useOdds ratioRelative riskDose-response associationDate of admissionSeverity of illnessIndependent dose-response associationsRace/ethnicityInpatient deliriumIndex dateMedication exposureRole of alcoholHIV statusMultivariable analysisMedication countNeurocognitive dysfunctionUnderappreciated causeDeliriumHigh incidencePWHMedicationsPWOHLogistic regression
2022
Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old
Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old. Pharmacoepidemiology And Drug Safety 2022, 31: 1056-1074. PMID: 35780391, PMCID: PMC9464694, DOI: 10.1002/pds.5506.Peer-Reviewed Original ResearchConceptsLevel of polypharmacyRace/ethnicityPIM prevalencePrevalence of PIMsInappropriate medication useElectronic health recordsCommon PIMsPharmacy fillsPROMPT criteriaInappropriate medicationsOlder patientsMedication usePsychotropic medicationsRefill recordsPolypharmacyPatientsVeterans AffairsMedicationsPrevalenceHealth recordsFiscal year 2016AgeMeaningful differencesSexTarget age
2020
Polypharmacy and frailty among persons with HIV
Sung M, Gordon K, Edelman EJ, Akgün KM, Oursler KK, Justice AC. Polypharmacy and frailty among persons with HIV. AIDS Care 2020, 33: 1492-1499. PMID: 32880183, PMCID: PMC7925692, DOI: 10.1080/09540121.2020.1813872.Peer-Reviewed Original ResearchConceptsNon-ARV medicationsVeterans Aging Cohort StudyFrailty-related phenotypeLow physical activityAging Cohort StudyCross-sectional studyWarrants further studyUninfected participantsAntiretroviral therapyCohort studyRefill dataAdjusted analysisViral loadPolypharmacyPhysical activityGeneral populationMedicationsPLWHFrailtyStrong associationFurther studiesHIVPrimary predictorAssociationLarge proportion
2018
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, Team V. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018, 32: 739-749. PMID: 29543653, PMCID: PMC5868488, DOI: 10.1097/qad.0000000000001756.Peer-Reviewed Original ResearchConceptsAdverse health outcomesHIV statusUninfected individualsVACS IndexMedication countUS Veterans Affairs Healthcare SystemHealth outcomesVeterans Affairs Healthcare SystemRisk of hospitalizationSeverity of illnessHIV-1 RNAHIV-positive individualsRisk of mortalityDose responseRace/ethnicityPolypharmacyFiscal year 2009HospitalizationMedicationsMortalityHealthcare systemAntiretroviralsOutcomesAssociationRisk
2016
Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans
Han JH, Gordon K, Womack JA, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Bisson GP. Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. Diabetes Care 2016, 40: 218-225. PMID: 27634393, PMCID: PMC5250696, DOI: 10.2337/dc16-0718.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack or African AmericanBlood GlucoseBody Mass IndexComparative Effectiveness ResearchDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlycated HemoglobinHispanic or LatinoHIV InfectionsHumansHypoglycemic AgentsLongitudinal StudiesMaleMetforminMiddle AgedSulfonylurea CompoundsThiazolidinedionesVeteransWhite PeopleConceptsType 2 diabetesDiabetic medicationsHIV infectionHispanic patientsPoor responseGlycemic responseOral diabetic medicationsLongitudinal cohort studyBaseline HbAGlycemic effectivenessHIV-InfectedUninfected veteransMedication initiationCohort studyOral medicationsWhite patientsPotential confoundersClinical covariatesMedicationsHIVPatientsType 2Comparative effectivenessPropensity scoreDiabetes